31. Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: Understanding nimotuzumab's clinical effects. We report a 57-year-old female with seropositive rheumatoid arthritis and autoimmune hemolytic anemia. For these, she was on weekly oral methotrexate 10 mg and daily oral prednisolone 10 mg continuously for 6 years. She presented to us with fever, weakness, exertional dyspnea, and weight loss. Blood investigations revealed pancytopenia with hemoglobin 6.5 g/dl, total WBC 2400/mm 3 , neutrophils 55%, lymphocytes 30%, and platelets 78,000/mm 3 . Bone marrow aspiration and biopsy revealed diffuse infiltration by sheets of large lymphoid cells which were strongly positive for CD45, CD20, PAX5, BCL-2, and focal positive for MUM1. The Ki67 proliferation index was 40%. Cells were negative for TdT, CD3, CD5, and CD7. Baseline positron emission tomography [ Figure 1 ] showed diffuse hypermetabolic activity of whole of the skeleton without the involvement of lymph nodes, spleen, or liver.
Thus, the patient was diagnosed to have bone marrow limited DLBCL. She was treated with six cycles of R-mini CHOP chemotherapy because of poor performance status. Bone marrow evaluation after chemotherapy showed normal cellularity with no features of lymphoma. She is on regular follow-up with normal blood counts and no evidence of disease 12 months from the end of treatment.
DLBCL comprises 31% of all NHL in Western countries and 37% of B-NHL worldwide. Median age at presentation is the 6 th decade. [2] PBM-DLBCL is a very rare entity, and hence, the clinical, pathologic, and prognostic aspects of this subtype of lymphoma have not been clearly established. Available literature shows that it is associated with dismal prognosis and poor outcome. The WHO classification of lymphoid neoplasms divides DLBCL in to four site-specific subtypes, namely primary central nervous system lymphoma, primary effusion lymphoma, DLBCL of leg type, and primary mediastinal B-cell lymphoma. [1] This updated classification does not recognize DLBCL exclusively affecting the bone marrow as separate disease entity. [1] The diagnostic criteria for PBM lymphoma are as follows (1) isolated bone marrow infiltration by lymphoma cells regardless of peripheral blood involvement, (2) no evidence of lymph nodal or extranodal disease detectable by physical examination or imaging, (3) no evidence of localized bone tumors, (4) no features of bone trabeculae destruction in the trephine biopsy, and (5) exclusion of leukemias and lymphomas that primarily involve the bone marrow. [3] In a retrospective review conducted by the International Extranodal Lymphoma Study Group, 21 cases fulfilling the criteria were found, of which the subtypes noted were DLBCL (n = 15), follicular lymphoma (n = 4), and peripheral T-cell lymphoma not otherwise specified (NOS) (n = 2). [3] In our patient, all the above criteria for the diagnosis of PBM-DLBCL were fulfilled. A literature search for arthritis associated with PBM-DLBCL identified only one report where a patient with seronegative polyarthritis developed bone marrow limited high-grade NHL. [4] Due to the extreme rarity of PBM-DLBCL, at present, these patients are managed similar to those with DLBCL-NOS with R-CHOP chemotherapy. The possibility that prolonged use of methotrexate and steroids may have altered the characteristics of DLBCL in our patient should be considered. Whether the distribution of DLBCL in the marrow rather than lymph nodes and spleen has any adverse bearing on the prognosis and whether alternative chemotherapy regimens are required for such patients are as yet unclear.
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Nil. its unique mechanism of action, distinct response patterns were observed and considered to be efficacy of the drug. Approximately 30% of patients treated with ipilimumab had disease control according to traditional RECIST criteria. They either had complete, partial response or stable disease. Some patients initially showed stable disease and then showed a decrease in tumor mass. The most interesting finding was that there was an initial increase in tumor mass and/or appearance of new lesions followed by decrease in the tumor mass or the tumor stopped growing further (stable disease). [3] Ipilimumab not only revised the way response is evaluated, but also showed unique emergent side effects because of its unique mechanism of action. The new set of guidelines named as immune-related adverse events (irAEs) was introduced. These side effects included hypophysitis, colitis, hepatitis, pneumonitis, and rash. There are increasing case reports of patients who develop irAEs resembling inflammatory and rheumatic diseases such as arthritis, nephritis, myositis, and polymyalgia-like syndromes, and even type I diabetes in adults. [4] No wonder that such a landmark drug had many twists in the patents which made it one of the most twisted affairs. The University of California, Berkeley, had experience to take the research and patents till preclinical stage only, but they patented clinical application of the invention in 1995 and moved ahead with licensing it out to a small company NeXstar Pharmaceuticals, which later on got merged with the biopharmaceutical company, Gilead Sciences Inc. Gilead sublicensed the rights to Medarex in 1999. Bristol-Myers Squibb (BMS) acquired Medarex in 2009. But, during this period, Medarex and Pfizer had signed an agreement in 2004 for co-development in spite of the fact that Pfizer was already into the development of its own anti-CTLA CP-675,206 (later named as tremelimumab). However, this collaboration lasted for a short duration, and finally, the product landed with BMS in 2005, who developed it further till commercialization. BMS had patented CTLA as a stimulator of T-cells and this prevented Dr. Allison to find a suitable developer for this drug before Medarex stepped in, as the patent position of this drug was considered "dirty" by potential investors.
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Letter to the Editor Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer DOI: 10.4103/sajc.sajc_199_18
Dear Editor, Alectinib is a highly selective, potent inhibitor of anaplastic lymphoma kinase (ALK). Phase 2 data suggest that alectinib elicits response in 46% with crizotinib-resistant disease, [1] making it a better alternative to chemotherapy. We describe a case of crizotinib-resistant ALK + non-small-cell lung cancer (NSCLC) and our experience with alectinib as third-line tyrosine kinase inhibitor (TKI) therapy.
A 47 year-old female was evaluated for cough in September 2014. Supraclavicular node biopsy confirmed lung cancer of adenosquamous histology and ALK was amplified on fluorescence in situ hybridization. Positron emission tomography-computed tomography (CT) and magnetic resonance imaging brain showed right-lobe lung lesion, nodal metastasis, and brain metastasis. She was started on crizotinib in October 2014. She had clinical
